OncoMatch/Clinical Trials/NCT05717153
Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma
Is NCT05717153 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including Eflornithine and Polyamine Transport Inhibitor AMXT-1501 Dicaprate for diffuse glioma.
Treatment: Eflornithine · Polyamine Transport Inhibitor AMXT-1501 Dicaprate · Microdialysis — This early phase I trial studies brain tumor (glioma) metabolism in response to eflornithine (DFMO) and polyamine transport inhibitor AMXT-1501 dicaprate (AMXT 1501) in patients with diffused or high grade glioma. Brain tumors use and produce certain molecules to survive and grow. DFMO is an irreversible inhibitor of ornithine decarboxylase, the enzyme catalyzing polyamine synthesis. AMXT 1501 is a polyamine transport inhibitor which prevents uptake of polyamines from the extracellular environment. This trial is being done to analyze how DFMO and AMXT 1501 affect brain tumor metabolism based on the molecules in the tumor's fluid.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Lab requirements
Blood counts
ANC >= 1.5 x 10^9/L, platelets >= 100 x 10^9/L, hemoglobin >= 9 g/dL, all without transfusion within 7 days preceding the lab assessment (obtained <= 14 days prior to registration); aPTT or PTT <= 1.5 x ULN
Kidney function
serum creatinine <= 1.5 x ULN or creatinine clearance >= 60 mL/min/1.73 m^2 for patients with serum creatinine levels above 1.5 x ULN (obtained <= 14 days prior to registration)
Liver function
AST and ALT <= 2.5 x ULN; total serum bilirubin <= 1.5 x ULN (obtained <= 14 days prior to registration)
ANC >= 1.5 x 10^9/L without transfusion within 7 days preceding the lab assessment (obtained <= 14 days prior to registration); Platelet >= 100 x 10^9/L, without transfusion within 7 days preceding the lab assessment (obtained <= 14 days prior to registration); Hemoglobin >= 9 g/dL, without transfusion support within 7 days preceding the lab assessment (obtained <= 14 days prior to registration); aPTT or PTT <= 1.5 x ULN (obtained <= 14 days prior to registration); AST and ALT <= 2.5 x ULN (obtained <= 14 days prior to registration); Total serum bilirubin <= 1.5 x ULN (obtained <= 14 days prior to registration); Serum creatinine <= 1.5 x ULN or creatinine clearance >= 60 mL/min/1.73 m^2 for patients with serum creatinine levels above 1.5 x ULN (obtained <= 14 days prior to registration)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic in Rochester · Rochester, Minnesota
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify